1
|
Andrés R, Mayordomo JI, Zaballos P, Rodino J, Isla D, Escudero P, Elosegui L, Filipovich E, Saenz A, Polo E, Tres A. Prognostic Value of Serum S-100B in Malignant Melanoma. TUMORI JOURNAL 2018; 90:607-10. [PMID: 15762365 DOI: 10.1177/030089160409000613] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background Although there is no established tumor marker of proven value for patients with melanoma, high serum levels of S-100B protein have been found in patients with melanoma and distant metastases. This study was performed to assess the prognostic value of this marker. Methods and Study Design Serum S-100B protein was measured by means of the LIA-mat System 300 (Sangtec S-100B LIA, AB Sangtec Medical, Bromma, Sweden) in 85 patients with melanoma. Results Mean serum S-100B protein was 0.075 μg/L (range, 0.001-0.470) in 66 patients with non-metastatic melanoma (stage I-III) versus 0.441 μg/L (range, 0.001-16.840) in 19 patients with metastatic melanoma (stage IV) (P <0.001, Mann Whitney U test). The median follow-up time was 329 days. Serum levels above 0.150 μg/L were found in 10 of patients with non-metastatic melanoma (15.2%) and in 17 of 19 patients with metastatic disease (89.4%). Median survival was 256 days for the 27 patients with serum S-100B levels above 0.150 μg/L versus 561 days for the 58 patients with normal values (P <0.3973). Conclusion Serum S-100B is a useful tumor marker in melanoma.
Collapse
Affiliation(s)
- Raquel Andrés
- Division of Medical Oncology, University Hospital, Zaragoza, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Res 2018; 26:354-60. [PMID: 27206057 DOI: 10.1097/cmr.0000000000000269] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Serum markers can be important tools for prognostic classification and treatment monitoring in cancer patients. The MAP-kinase pathway, which is upregulated in the majority of melanoma patients, can be activated by hepatocyte-growth factor (HGF) through the proto-oncogene c-MET. The aim of this study was to evaluate the predictive and prognostic value of circulating HGF in terms of treatment outcome and survival compared with a widely established serum marker, protein S-100B, in patients with advanced metastatic melanoma. HGF and S-100B were measured in serum samples of 101 patients with metastatic melanoma (American Joint Committee on Cancer stage IV) before and after treatment and 50 patients with stage I/II melanoma. HGF and S-100B correlated significantly with the stage of disease (P=0.032 and P<0.001, respectively). In stage IV melanoma patients, baseline serum levels of HGF and S-100B were significantly associated with treatment response (P=0.012 and 0.006, respectively). Furthermore, the Cox regression analysis confirmed that serum levels of HGF and S-100B proved to have a significant prognostic impact on progression-free survival (hazard ratio=1.39 and 1.29, respectively) and overall survival (hazard ratio=1.27 and 1.29, respectively) in advanced metastatic melanoma patients. In melanoma patients, serum levels of HGF and S-100B correlate significantly with the stage of disease. In stage IV melanoma, both markers are prognostic factors and correlate significantly with progression-free survival and overall survival. Measurement of serum HGF levels might be a useful additional tool in the management of melanoma patients.
Collapse
|
3
|
A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. Eur J Surg Oncol 2017; 43:1753-1759. [DOI: 10.1016/j.ejso.2017.07.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Revised: 06/23/2017] [Accepted: 07/13/2017] [Indexed: 11/20/2022] Open
|
4
|
[Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?]. Bull Cancer 2014; 101:354-7. [PMID: 24793626 DOI: 10.1684/bdc.2014.1943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The prognosis of metastatic melanoma, despite many important and recent progresses, remains poor. The detection of microscopic disease must be a key point in fundamental and clinical research. Current recommendations, with clinical and radiological monitoring, only permit to detect macroscopic relapses. No seric tumor marker is presently sufficiently reproducible and determinant to be used in clinical practice to precociously diagnose a relapse. The sentinel lymph node procedure is currently the only technique largely used to determine microscopic metastasis. This technique allows defining a group of patients with poor prognosis but its therapeutic impact remains discussed. Completion lymph node dissection of the area after positive sentinel lymph node is currently performed but its real benefit to improve overall survival must be proved. Interferon is now the only treatment approved in adjuvant setting, but its interest remains discussed. Therapeutic trials are ongoing to really identify patients who could benefit from adjuvant treatment with interferon. Other trials probably more attractive (anti-CTLA4, BRAF and MEK inhibitors), with molecules recently approved in metastatic phase are also ongoing.
Collapse
|
5
|
Loquai C, Müller-Brenne T, Schadmand-Fischer S, Grabbe S. Serum S100B Levels Correlate with Clinical Benefit in a Metastatic Melanoma Patient Treated by CTLA-4 Blockade: A Case Report. ACTA ACUST UNITED AC 2013; 36:578-81. [DOI: 10.1159/000355159] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, Kurschat P. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res 2012; 304:397-400. [DOI: 10.1007/s00403-012-1228-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Revised: 02/28/2012] [Accepted: 02/29/2012] [Indexed: 01/11/2023]
|
7
|
Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma. Int J Biol Markers 2011; 26:82-7. [PMID: 21607923 DOI: 10.5301/jbm.2011.8344] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/11/2011] [Indexed: 11/20/2022]
Abstract
Cutaneous malignant melanoma (CMM) is the most serious type of skin cancer because of its tendency to metastasize. The prognosis and therapeutic management of patients are primarily based on clinical criteria (number of cancerous lymph nodes and/or the presence of distant metastases) and histopathological criteria (tumor depth, presence of ulceration and mitotic index). Although these factors are informative in advanced stages of the disease, they are less important in the early stages. In recent years, a number of attempts have been made to identify new serological prognostic biomarkers, especially for early forms of CMM. The recent development of proteomic techniques may offer new perspectives in this field. This article details the considerations of each of the proteomic techniques used today and describes the results of the most recent clinical studies conducted to identify new potential prognostic serum biomarkers for CMM. However, independent and large validation studies are needed before such markers can be used in everyday clinical practice.
Collapse
|
8
|
Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 2011; 48:695-702. [PMID: 21917447 DOI: 10.1016/j.ejca.2011.08.007] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Revised: 06/15/2011] [Accepted: 08/15/2011] [Indexed: 10/17/2022]
Abstract
BACKGROUND Serum markers can be important tools for the prognostic classification and the treatment monitoring in cancer patients. Recently, the potential new serum marker YKL-40 has been introduced for patients with malignant melanoma. The purpose of this study was to assess the prognostic value of YKL-40 in stage IV melanoma patients regarding treatment outcome and survival compared to the established markers LDH and serum S-100B and to evaluate their ability to discriminate between different stages of the disease. METHODS YKL-40, LDH and S-100B were measured in serum samples of 50 patients with stage I/II melanoma and 61 patients with metastatic melanoma before and after treatment. Univariate and multivariate analyses were performed to determine prognostic factors. RESULTS YKL-40, S-100B and LDH correlated significantly with the stage of disease. In stage IV melanoma patients, only the baseline serum levels of S-100B were significantly associated with treatment response (p=0.031), but not those of LDH (p=0.193) or YKL-40 (p=0.186). We found a strong correlation between treatment response and unchanged or declining S-100B levels over time (p=0.003, OR: 9.52, 95%-CI: 1.87-47.62), but no significant correlation between treatment response and serum changes for LDH (p=0.534) and YKL-40 (p=0.306), respectively. In the Cox Regression analysis, only the serum levels of S-100B proved to have a significant prognostic impact on survival (p<0.0001). CONCLUSION In melanoma patients, serum levels of YKL-40, S-100B and LDH correlate significantly with the stage of disease. In stage IV melanoma, S100-B significantly correlates with treatment response and survival and is superior to LDH and YKL-40.
Collapse
Affiliation(s)
- Friederike Egberts
- Department of Dermatology, Schleswig-Holstein University Hospital, Campus Kiel, Germany.
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
Background Morphologic and histopathologic markers have been the backbone for the classification and prognostic assessment of melanoma. Availability of an increasing number of molecular markers, however, provides the potential for refining diagnostic and prognostic categories in this disease. Methods We reviewed the recent data that are accumulating concerning gene expression and genetic profiling and related these to clinical aspects of the disease. Results Multiple biomarkers have now been described, and their biologic significance is being established. In addition, several candidate molecules involved in mela-noma pathogenesis have been identified. Conclusions The process of biomarker identification and validation is providing a rapidly changing molecular view of melanoma, a strategy that is necessary for developing truly stratified or even personalized prevention or management.
Collapse
Affiliation(s)
- Selma Ugurel
- Department of Dermatology, Julius-Maximilians University, Wüirzburg, Germany
| | - Jochen Utikal
- Department of Dermatology, Julius-Maximilians University, Wüirzburg, Germany
| | - Jüurgen C Becker
- Department of Dermatology, Julius-Maximilians University, Wüirzburg, Germany
| |
Collapse
|
10
|
Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL. A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients. Cancer Invest 2009; 25:285-93. [PMID: 17661202 DOI: 10.1080/07357900701208634] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
PURPOSE There is no consensus regarding the optimal tumor markers for melanoma. We compared 3 tumor markers, TA90-immune complex (TA90IC), melanoma-inhibiting activity (MIA) protein, and S100B protein in Stage III melanoma patients undergoing adjuvant vaccine immunotherapy. EXPERIMENTAL DESIGN The serum of 75 patients representing 3 prognostic cohorts was assayed for the tumor markers prior to initiating immunotherapy and at 6 follow-up time points. Upper limits of normal for TA90IC, MIA and S100B were set at OD 0.41, 8.5 ng/ml, and 2.5 microg/l, respectively. RESULTS At least 1 marker became elevated prior to 41 (80 percent) of 51 recurrences. TA90IC was the earliest elevated marker in 29 (57 percent), MIA in 11 (22 percent), and S100B in 4 (8 percent). Multivariate regression analysis revealed that TA90IC was an independent predictor of survival when elevation occurred between 2 weeks and 3 months, whereas MIA was an independent predictor at 4-6 months. In the poor prognostic cohort, mean values for MIA and S100B increased progressively, whereas TA90IC exhibited a parabolic curve. CONCLUSION In this patient population, TA90IC and MIA were complementary; elevation of the immune complex preceded elevation of the tumor antigen in patients who developed recurrence. Additional studies in populations not receiving vaccine will further clarify the clinical utility of these assays.
Collapse
Affiliation(s)
- Mark B Faries
- John Wayne Cancer Institute, Sant Monica, CA 90404, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res 2008; 18:412-9. [DOI: 10.1097/cmr.0b013e328315c690] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma. Am J Clin Oncol 2008; 31:335-9. [DOI: 10.1097/coc.0b013e318162f11e] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 2007; 298:469-77. [PMID: 17221215 PMCID: PMC1800369 DOI: 10.1007/s00403-006-0726-5] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Revised: 12/06/2006] [Accepted: 12/06/2006] [Indexed: 01/11/2023]
Abstract
Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Collapse
MESH Headings
- Biomarkers, Tumor/blood
- Carcinoma, Squamous Cell/blood
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/pathology
- Humans
- Lymphoma, T-Cell, Cutaneous/blood
- Lymphoma, T-Cell, Cutaneous/diagnosis
- Lymphoma, T-Cell, Cutaneous/pathology
- Melanoma/blood
- Melanoma/diagnosis
- Predictive Value of Tests
- Prognosis
- Skin Neoplasms/blood
- Skin Neoplasms/diagnosis
- Skin Neoplasms/pathology
Collapse
Affiliation(s)
- Jochen Utikal
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany
| | - Dirk Schadendorf
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany
- Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany
| | - Selma Ugurel
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany
- Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany
| |
Collapse
|
14
|
Vitzthum J, Dörr HD, Meineke V. Ultraviolet B exposure could influence the interpretation of serum S100beta levels in patients with malignant melanoma. Br J Dermatol 2007; 156:772-3. [PMID: 17493078 DOI: 10.1111/j.1365-2133.2006.07737.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D. Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients. J Clin Oncol 2005; 23:5088-93. [PMID: 16051955 DOI: 10.1200/jco.2005.03.164] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PurposeCurrently known serum biomarkers do not predict clinical outcome in melanoma. S100-β is widely established as a reliable prognostic indicator in patients with advanced metastatic disease but is of limited predictive value in tumor-free patients. This study was aimed to determine whether molecular profiling of the serum proteome could discriminate between early- and late-stage melanoma and predict disease progression.Patients and MethodsTwo hundred five serum samples from 101 early-stage (American Joint Committee on Cancer [AJCC] stage I) and 104 advanced stage (AJCC stage IV) melanoma patients were analyzed by matrix-assisted laser desorption/ionisation (MALDI) time-of-flight (ToF; MALDI-ToF) mass spectrometry utilizing protein chip technology and artificial neural networks (ANN). Serum samples from 55 additional patients after complete dissection of regional lymph node metastases (AJCC stage III), with 28 of 55 patients relapsing within the first year of follow-up, were analyzed in an attempt to predict disease recurrence. Serum S100-β was measured using a sandwich immunoluminometric assay.ResultsAnalysis of 205 stage I/IV serum samples, utilizing a training set of 94 of 205 and a test set of 15 of 205 samples for 32 different ANN models, revealed correct stage assignment in 84 (88%) of 96 of a blind set of 96 of 205 serum samples. Forty-four (80%) of 55 stage III serum samples could be correctly assigned as progressors or nonprogressors using random sample cross-validation statistical methodologies. Twenty-three (82%) of 28 stage III progressors were correctly identified by MALDI-ToF combined with ANN, whereas only six (21%) of 28 could be detected by S100-β.ConclusionValidation of these findings may enable proteomic profiling to become a valuable tool for identifying high-risk melanoma patients eligible for adjuvant therapeutic interventions.
Collapse
Affiliation(s)
- Shahid Mian
- Interdisciplinary Biomedical Research Centre, School of Science, Nottingham Trent University, Clifton, Nottingham NG11 8NS, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Smit LHM, Nieweg OE, Korse CM, Bonfrer JMG, Kroon BBR. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol 2005; 90:66-9; discussion 69-70. [PMID: 15844182 DOI: 10.1002/jso.20238] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND AND OBJECTIVES The clinical utility of the tumor marker serum S-100B has been described in determining prognosis, for early diagnosis of recurrence and for disease monitoring in melanoma patients. Sentinel node biopsy is increasingly used as staging procedure for patients with clinically localized melanoma. The aim of this study was to determine the value of serum S-100B in melanoma patients before and after sentinel lymph node biopsy. METHODS S-100B values were measured prior to sentinel node biopsy in 89 patients and during follow-up (median 41 months; range 7-73 months) in 88 patients. The detection limit is < or =0.08 microg/L. In our laboratory levels of 0.16 microg/L and above are classified as increased. RESULTS Twenty-four patients had tumor-positive sentinel nodes, 65 had tumor-free sentinel nodes. The median S-100B value prior to the operation was < or =0.08 microg/L for all patients. Sensitivity and specificity of S-100B to predict the tumor-status of the sentinel node were 13% and 98%, respectively. Eighteen patients developed a melanoma-related recurrence. Sensitivity for early diagnosis of recurrence was 55% and 33%, respectively for patients with a positive versus a negative sentinel node. Specificity was 100% in both patient groups. CONCLUSIONS S-100B is not useful in predicting the tumor-status of the sentinel node, and questionable for early diagnosis of recurrence afterwards. Elevation of serum S-100B is highly specific for melanoma recurrence.
Collapse
Affiliation(s)
- Léonie H M Smit
- Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
| | | | | | | | | |
Collapse
|
17
|
Abstract
Tumor markers in the serum of cancer patients have an important role in clinical diagnosis and in prognosis, and also in the monitoring of the patients' disease and response to therapy over time. The serum markers currently available for melanoma have only limited clinical use. Those most widely used in clinical applications are S100-beta, melanoma inhibitory activity, and lactate dehydrogenase; there are close correlations between the serum concentrations of these and tumor load. Regular determination of S100-beta and MIA levels during follow-up can therefore be used for early detection of a tumor relapse in melanoma patients, increased serum concentrations of these marker proteins being indicative of tumor growth. Patients with distant metastases from melanoma who present with elevated serum levels of S100-beta, MIA, or LDH have poorer overall survival than do patients whose serum concentrations are within normal ranges. These three markers can also be used to monitor the course of disease and therapy outcome in patients with distant metastases. Since there are no marker proteins for melanoma that are not dependent on tumor load, it is not currently possible to forecast the survival of patients who are tumor free after surgery. Serum markers are also not suitable for screening or for the diagnosis of primary melanomas.
Collapse
Affiliation(s)
- S Ugurel
- Klinische Kooperationseinheit Dermato-Onkologie, Deutsches Krebsforschungszentrum Heidelberg/Universitätshautklinik Mannheim.
| |
Collapse
|
18
|
Seraglia R, Vogliardi S, Allegri G, Comai S, Lise M, Rossi CR, Mocellin S, Scalerta R, Ragazzi E, Traldi P. Search for melanoma markers in plasma and serum samples. EUROPEAN JOURNAL OF MASS SPECTROMETRY (CHICHESTER, ENGLAND) 2005; 11:353-60. [PMID: 16107750 DOI: 10.1255/ejms.751] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Fourteen blood samples from patients with melanoma and eleven blood samples from healthy subjects were analyzed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. The study was focussed on species of low molecular weight, in the range 800-5000 Da, present in plasma and sera. While for healthy subjects plasma samples lead to the production of a higher number of ionic species, for melanoma patients a high number of diagnostic ions, present with high frequency and with quite high relative abundance, are present in particular in serum samples and to a lesser extent also in plasma. Since plasma samples are obtained more easily in comparison to sera, it is possible to suggest that also plasma can be used for these studies.
Collapse
Affiliation(s)
- Roberta Seraglia
- CNR, Istituto di Scienze e Tecnologie Molecolari sezione di Padova, Corso Stati Uniti 4, I35127 Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res 2004; 13:587-93. [PMID: 14646622 DOI: 10.1097/00008390-200312000-00008] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A wide range of molecules have been investigated as tumour markers in melanoma, most of which are not suitable for use by clinical oncologists for the detection of fast and unpredictable metastatic dissemination. We have already shown that the serum L-dopa/L-tyrosine ratio (an index of tyrosinase functional activity) correlates with the tumour burden and in some cases predicted disease progression in metastatic melanoma patients. We examined the potential value of this ratio for the follow-up, therapy monitoring and prognosis in melanoma compared with a reference marker (S100B, a melanoma-associated antigen). Sixty melanoma patients (24 stage I-II, 18 stage III, 18 stage IV, American Joint Committee on Cancer staging) were entered into the study, sampled two to eight times (before and after therapy) and were followed for up to 30 months. Serum L-dopa and L-tyrosine were determined by high performance liquid chromatography and S100B by an immunoluminometric assay. In stage III patients with elevated marker concentration, lymph node dissection decreased the S100B level (from 0.27 to < 0.13 microg/l, P=0.008), but not the L-dopa/L-tyrosine ratio. Chemotherapy decreased the L-dopa/L-tyrosine ratio by 38% (P =0.04) and the S100B level by 45% (P = 0.02) in stage IV responders. During follow-up, patients with marker levels within normal limits (n=19) had stable disease, except for two stage II patients. In patients with progressive disease (n=20), an increase in one or both markers was observed. Stage IV patients with high L-Dopa/L-Tyrosine ratio (above 20 x 10-5) at inclusion had shorter survival (3 months), while patients with low levels had longer survival (15 months). Levels of S100B had no impact on survival, as all stage IV patients (with levels below or above 0.38 microg/l) had the same survival (5 months). The serum L-dopa/L-tyrosine ratio may be influenced by successful therapy and levels at inclusion may correlate with prognosis in stage IV patients. Levels of these two markers in other biological fluids such as cerebrospinal fluid and tumour exudates may be useful diagnostically and prognostically in difficult cases.
Collapse
|
20
|
Affiliation(s)
- D J Eedy
- Department of Dermatology, Craigavon Area Hospital Group Trust, 68 Lurgan Road, Portadown BT63 5QQ, U.K.
| |
Collapse
|
21
|
Abstract
Understanding the fundamental aspects of the pathology of melanoma is crucial for the surgeon to deliver optimal care to the patient with melanoma. Pathology provides diagnostic data, offers prognostic information, and, to a large extent, directs management. This article reviews several aspects of the pathology of melanoma, with special relevance to the surgeon, including benign clinicopathologic simulators of melanoma, fundamental concepts of the pathology of melanoma, histopathologic prognostic factors of melanoma, approach to lymph nodes, and implications of the revised staging system.
Collapse
Affiliation(s)
- Vincent Liu
- Massachusetts General Hospital, Dermatopathology Unit, Warren 829, 55 Fruit Street, Boston, MA 02114, USA.
| | | |
Collapse
|
22
|
Ragazzi E, Vogliardi S, Allegri G, Costa CVL, Lise M, Rossi CR, Seraglia R, Traldi P. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2003; 17:1511-1515. [PMID: 12820221 DOI: 10.1002/rcm.1080] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
|